Chongqing Genrix Biopharmaceutical Co., Ltd. (SHA:688443)
China flag China · Delayed Price · Currency is CNY
30.80
+0.01 (0.03%)
At close: Apr 29, 2026

SHA:688443 Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2019
Market Capitalization
11,2949,9889,20014,649--
Upgrade
Market Cap Growth
10.91%8.57%-37.20%---
Upgrade
Enterprise Value
10,0258,7207,40512,246--
Upgrade
Last Close Price
30.8027.2425.0939.95--
Upgrade
PS Ratio
48.9543.29305.7012091.50--
Upgrade
PB Ratio
6.325.594.335.26--
Upgrade
P/TBV Ratio
6.475.724.425.35--
Upgrade
EV/Sales Ratio
43.4537.79246.0410108.38--
Upgrade
Debt / Equity Ratio
0.590.590.390.2326.891.83
Upgrade
Net Debt / Equity Ratio
-0.71-0.71-0.76-0.8217.030.42
Upgrade
Net Debt / EBITDA Ratio
2.682.682.053.05-0.87-0.48
Upgrade
Net Debt / FCF Ratio
--2.604.86-1.53-0.37
Upgrade
Asset Turnover
--0.010.0000.05
Upgrade
Inventory Turnover
--0.11-0.040.80
Upgrade
Quick Ratio
--14.1221.332.275.15
Upgrade
Current Ratio
--15.0522.153.166.15
Upgrade
Return on Equity (ROE)
-27.40%-27.40%-32.47%-56.97%-337.99%-
Upgrade
Return on Assets (ROA)
---15.62%-21.82%-38.85%-25.14%
Upgrade
Return on Capital Employed (ROCE)
---28.30%-23.00%-73.10%-32.90%
Upgrade
Earnings Yield
-4.75%-5.37%-8.67%-5.47%--
Upgrade
FCF Yield
---6.75%-3.20%--
Upgrade
Buyback Yield / Dilution
0.72%0.72%-14.63%-16.79%0.32%-
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.